hBD-1 vs Leu-enkephalin
Head-to-head comparison of hBD-1 (Human beta-defensin 1) and Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | hBD-1 | Leu-enkephalin |
|---|---|---|
| Category | Dental & Oral | Pain Management |
| Full Name | Human beta-defensin 1 | Tyr-Gly-Gly-Phe-Leu |
| Molecular Weight | 4490 Da | 555.63 Da |
| Half-Life | minutes to hours | 1-5 minutes in plasma |
| Amino Acids | 36 | 5 |
| Typical Dose | 1-10 µg/mL in experimental studies | 0.1-5 ug per animal |
| Route | Topical/Intraoral | Intrathecal / intracerebroventricular |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 1000 |
| Research Status | Pre-clinical | Pre-clinical |
hBD-1 Benefits
- ✓oral innate immunity
- ✓broad antimicrobial activity
- ✓biofilm suppression
- ✓periodontal support
Leu-enkephalin Benefits
- ✓delta-opioid activity
- ✓endogenous analgesic model
- ✓receptor-selective pharmacology
- ✓nociception pathway research
hBD-1 Dosing
topical peptide exposure|cell-culture or mucosal models|repeat low-dose application in research
Leu-enkephalin Dosing
Intrathecal 0.1-5 ug per animal|Intracerebroventricular 0.1-2 ug per animal|In vitro 1-100 nM
hBD-1 Side Effects
- ⚠protease degradation
- ⚠local irritation at high dose
- ⚠limited stability in saliva
Leu-enkephalin Side Effects
- ⚠sedation
- ⚠constipation-like opioid effects
- ⚠very short plasma stability
Research Overview
hBD-1
hBD-1 has been studied as part of the oral mucosal defense system and is linked to host resistance against dental pathogens. Research spans periodontitis, candidiasis, and epithelial barrier biology.
Leu-enkephalin
Leu-enkephalin is a standard tool in opioid receptor and pain-transmission research because it helps distinguish delta- from mu-preferring signaling. Its research value is high, but its clinical utility is limited by rapid enzymatic breakdown and delivery challenges.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.